Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
September 2013

Suvorexant: A New Hypnotic
The FDA has approved the new hypnotic suvorexant for the treatment of insomnia, but only at low doses.

Zonisamide to Combat Antipsychotic-Associated Weight Gain
Adjunctive treatment with zonisamide (Zonegran) may help prevent weight gain in patients being treated with antipsychotics.

Metabolic Abnormalities in Early Schizophrenia
For patients with schizophrenia, metabolic risk factors increase over time and may be related to the illness itself, attendant lifestyle factors, and medication.

In Brief
Iron Deficiency Anemia Linked to Increases in Psychiatric Disorders in Children and Adolescents; Postmenopausal Hormone Therapy Is Not Linked to Cognitive Impairment in Women 50 to 55 Years Old

Memantine Augmentation for MDD: A Negative Result
In a small trial of patients with depression who were incompletely responsive to treatment with antidepressant drugs, augmentation with memantine (Namenda) provided no benefit.

Oral Health, Schizophrenia, and Antipsychotic Agents
Individuals with chronic mental illnesses are more likely to have poor dental hygiene and nutrition; antipsychotic drugs that decrease salivary flow can increase problems with oral health.

Memantine Augmentation for MDD: A Negative Result

September 2013

We have noted a number of positive studies of the N-methyl-D-aspartate (NMDA) antagonist ketamine to treat major depressive disorder (MDD) (BTP 2010;33:37-38,44; 2007;30:4), which typically show rapid, robust, and sustained improvement in…

To view the rest of this article, please: